| Background | Programmed Death-Ligand 1 (PD-L1) , CD274, or B7 Homolog 1 (B7-H1) , is a transmembrane protein involved in suppressing the immune system and rendering tumour cells resistant to lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumour aggressiveness and risk of death. When considered in adjunct with CD8+ tumour-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small-cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma. |
Information sourced from Uniprot.org
![Anti-PD-L1 antibody [405.9A11] (STJ16101366)](https://cdn11.bigcommerce.com/s-zso2xnchw9/images/stencil/600x533/products/151875/346960/STJ16101366_1__26885.1681999190.jpg?c=1 "Anti-PD-L1 antibody [405.9A11] (STJ16101366)")
